Home    Back

Other: lengthening adalimumab dosing interval    (DrugBank: Adalimumab)

1 disease
IDDisease name (Link within this page)Number of trials
96Crohn disease1

96. Crohn disease    [ 2,209 clinical trials,   1,276 drugs,   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,209 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03172377
(ClinicalTrials.gov)		May 3, 201729/5/2017Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease PatientsLengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease PatientsCrohn Disease in Remission;Crohn DiseaseOther: Lengthening adalimumab dosing intervalRadboud UniversityErasmus Medical CenterActive, not recruiting18 YearsN/AAll174Phase 4Netherlands